Increased awareness and early diagnosis of ATTR-CM is crucial in helping to prolong patients lives and increase their quality of life whilst reducing the strain on healthcare services.

 

The diagnosis of ATTR-CM can be challenging, with patients on average experiencing a

from the initial onset of symptoms. This is largely due to the non-specific nature of the symptoms which mimic other common symptoms for heart conditions, often leading to a misdiagnosis of either Heart Failure (HF) or hypertrophic cardiomyopathy. 

 

These issues in delays significantly impact patients outcomes,

with a

median survival rate of 2.5 - 3.6 years

 

and a

50% increase in hospitalisations

in the year following diagnosis compared to HF patients